Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

Background: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been implicated in resistance to BEV. This phase II study...

Full description

Bibliographic Details
Main Authors: Hao Xie, Jacqueline M. Lafky, Bruce W. Morlan, Philip J. Stella, Shaker R. Dakhil, Gerald G. Gross, William S. Loui, Joleen M. Hubbard, Steven R. Alberts, Axel Grothey
Format: Article
Language:English
Published: SAGE Publishing 2020-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920910913

Internet

https://doi.org/10.1177/1758835920910913

Similar Items